MannKind (MNKD) Competitors $5.76 +0.27 (+4.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.84 +0.08 (+1.30%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. ALKS, LGND, FOLD, CLDX, BCRX, NVAX, INVA, OPK, DVAX, and ZBIOShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics BioCryst Pharmaceuticals Novavax Innoviva OPKO Health Dynavax Technologies Zenas BioPharma MannKind (NASDAQ:MNKD) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability. Do analysts prefer MNKD or ALKS? MannKind presently has a consensus price target of $11.17, suggesting a potential upside of 93.87%. Alkermes has a consensus price target of $42.00, suggesting a potential upside of 35.22%. Given MannKind's stronger consensus rating and higher probable upside, equities analysts plainly believe MannKind is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 Which has stronger valuation & earnings, MNKD or ALKS? Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$301.74M5.86$27.59M$0.1152.36Alkermes$1.56B3.29$367.07M$2.0814.93 Does the media refer more to MNKD or ALKS? In the previous week, Alkermes had 2 more articles in the media than MannKind. MarketBeat recorded 5 mentions for Alkermes and 3 mentions for MannKind. MannKind's average media sentiment score of 1.23 beat Alkermes' score of 0.06 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, MNKD or ALKS? MannKind has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Is MNKD or ALKS more profitable? Alkermes has a net margin of 23.15% compared to MannKind's net margin of 10.87%. Alkermes' return on equity of 24.86% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets MannKind10.87% -32.60% 7.81% Alkermes 23.15%24.86%17.14% Do institutionals & insiders hold more shares of MNKD or ALKS? 49.5% of MannKind shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 2.7% of MannKind shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAlkermes beats MannKind on 11 of the 17 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.68B$3.33B$6.09B$10.56BDividend YieldN/A2.27%5.68%4.70%P/E Ratio52.3722.1478.0526.71Price / Sales5.86416.32577.62178.63Price / Cash39.5647.2037.7961.25Price / Book-19.869.9312.556.56Net Income$27.59M-$52.80M$3.31B$277.70M7 Day Performance4.16%5.22%4.28%2.41%1 Month Performance7.87%13.01%7.85%9.30%1 Year Performance-11.25%25.18%71.37%31.22% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind4.0964 of 5 stars$5.76+4.9%$11.17+93.9%-10.3%$1.68B$301.74M52.37400Positive NewsALKSAlkermes4.5139 of 5 stars$29.04+4.1%$42.00+44.6%+9.5%$4.60B$1.56B13.961,800LGNDLigand Pharmaceuticals4.0664 of 5 stars$173.13+2.0%$176.50+1.9%+77.0%$3.33B$167.13M-43.2880Positive NewsFOLDAmicus Therapeutics4.2969 of 5 stars$7.94-3.6%$15.78+98.7%-22.3%$2.54B$528.29M-66.16480CLDXCelldex Therapeutics2.2006 of 5 stars$26.19+0.2%$46.13+76.1%-14.4%$1.74B$7.02M-8.70150Positive NewsBCRXBioCryst Pharmaceuticals4.0421 of 5 stars$7.55-1.0%$16.70+121.2%-3.6%$1.60B$450.71M-41.94530Analyst ForecastNVAXNovavax4.3169 of 5 stars$8.57+0.2%$14.29+66.7%-34.4%$1.39B$682.16M3.761,990Options VolumeINVAInnoviva4.838 of 5 stars$19.03+0.9%$42.75+124.6%-10.4%$1.19B$358.71M61.39100Analyst ForecastGap UpOPKOPKO Health4.0707 of 5 stars$1.47+1.4%$2.63+78.6%+3.3%$1.15B$713.10M0.002,997DVAXDynavax Technologies4.6065 of 5 stars$9.66-1.2%$24.33+151.9%-9.7%$1.15B$277.25M-21.00350Positive NewsZBIOZenas BioPharma1.4609 of 5 stars$20.57+2.4%$36.67+78.3%N/A$846M$5M0.00N/A Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Zenas BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
